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A single treatment with a CpG-containing immunostimulatory DNA sequence (ISS) given 
before allergen challenge can inhibit T helper type 2 cell (Th2)–mediated airway responses in 
animal models of allergic asthma; however, the mechanism of this inhibition remains largely 
undefined. Here, we demonstrate that airway delivery of ISS before allergen challenge in 
Th2-primed mice acts in two distinct ways to prevent the allergic responses to this challenge. 
The first is to prevent induction of cytokines from allergen-specific Th2 cells, as demonstrated 
by the nearly complete inhibition of Th2 cytokine production, Th2-dependent functional 
responses, and gene induction patterns. ISS inhibits the Th2 response by rendering lung 
antigen-presenting cells (APCs) unable to effectively present antigen to Th2 cells, but not to 
Th1 cells. This loss of APC function correlates with a reduced expression of costimulatory 
molecules, including programmed cell death ligand (PD-L)1, PD-L2, CD40, CD80, CD86, and 
inducible T cell costimulator, and of major histocompatibility complex class II on CD11c
 
  
 
APCs 
from the airways of ISS-treated mice. The second important action of ISS is inhibition of 
immunoglobulin E–dependent release of Th2 cytokines, especially interleukin 4, from basophils 
and/or mast cells in the airways of Th2-primed mice. Thus, inhibition by ISS of allergic 
responses can be explained by two novel mechanisms that culminate in the inhibition of the 
principal sources of type 2 cytokines in the airways.
 
CpG-containing immunostimulatory DNA
sequences (ISS) have been shown to inhibit the
major features of allergic asthma and airway
inflammation. Studies performed by us and
others have demonstrated that ISS inhibit the
development of airway hyperresponsiveness,
mucus production, and airway eosinophil infil-
tration in mouse asthma models (1–7). Treat-
ment with one single systemic dose of ISS
inhibits Th2 responses in the airways for a period
of 4 wk, in spite of ongoing allergen challenges
(5). ISS are effective when given before allergen
challenge as a preventive measure (3, 5, 6) and
have been demonstrated to reverse established
disease (4, 8). In long-term mouse asthma
models, ISS inhibit such lung-remodeling pa-
rameters as collagen deposition, goblet cell
hyperplasia, and thickening of the epithelial
basement membrane (9–11). Recently, similar
effects of ISS have been reported in a monkey
model for allergic asthma (12).
ISS activate the Toll-like receptor (TLR)-9
pathway (13) and promote the development of a
Th1 cell response both in vitro and in vivo (14,
15). ISS activate cells of the innate immune sys-
tem to generate cytokines, such as TNF-
 
 
 
, IL-
12, IFN-
 
 
 
, and indirectly, IFN-
 
 
 
 (14, 15). One
can envision that long-term treatment with ISS
through induction of IL-12 and IFNs would lead
to a rebalancing of Th1/Th2 responses, perhaps
ultimately leading to complete inhibition of the
Th2 response. A recent study in allergic rhinitis
patients treated during the ragweed season with
ISS conjugated to the dominant ragweed allergen
 
Amb a I
 
 demonstrated increased levels of IFN-
 
 
 
and reduced levels of IL-4 in nasal biopsies
obtained 16 wk after the ragweed season,
supporting this hypothesis (16).
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A key question, however, is how the immediate inhibi-
tory effects of ISS on the Th2 response can be explained. A
single treatment with ISS given just before allergen challenge
can completely block the allergen-induced Th2 response. A
direct effect on Th2 cells is unlikely, as T cells do not express
TLR-9 (13). However, other modes of action are possible
based on known activities of ISS. For example, cytokines or
mediators induced by ISS could inhibit effector functions
mediated by Th2 cytokines, such as IgE production, smooth
muscle hyperreactivity, and eosinophilia. Studies investigat-
ing whether the immediate inhibitory effects of ISS are me-
diated by IL-12 or IFN-
 
 
 
, however, give conflicting results
(4, 17–19). Some studies demonstrate that ISS inhibition of
allergen-induced eosinophil infiltration is partially dependent
on IFN-
 
  
 
(4), whereas others show that ISS inhibition of
allergen-induced Th2 responses is independent of ISS-
induced cytokines, such as IL-12 or IFN-
 
 
 
 (17–19). Alterna-
tively, inhibition by ISS could result from actions on cell
types required for Th2 activation, such as APCs. In this
study, we sought to elucidate how ISS exert their immediate
inhibitory effect on the allergic response and characterize
more precisely which pathways and cellular events of the
allergen-induced response are inhibited.
 
RESULTS
1018 ISS does not inhibit gene induction by IL-4 or IL-13
 
IL-4 and IL-13 play a central role in Th2 responses in the
respiratory tract, inducing airway hyperresponsiveness, mu-
cus overproduction, and eosinophil recruitment (20–22).
Many biological activities mediated by IL-4 and IL-13 are
known to be inhibited by cytokines inducible by ISS, such
as IL-12, IFN-
 
 
 
, and IFN-
 
 
 
 (23–28), suggesting that ISS
may inhibit the allergic airway response by antagonizing
the actions of IL-4 and IL-13. To test this, naive BALB/c
mice were treated intranasally with 20 
 
 
 
g 1018 ISS, con-
trol oligodeoxynucleotide (ODN), or saline, followed 1 d
later by 5 
 
 
 
g IL-4 or IL-13, also given intranasally. Prior
studies have shown optimal gene induction in the airways
between 3 and 12 h after treatment at this dose of IL-4 or
IL-13 (not depicted). The dose of 20 
 
 
 
g 1018 ISS was de-
rived from previous experiments demonstrating optimal in-
duction of ISS-inducible genes in the airways within a dose
range of 5–20 
 
 
 
g 1018 ISS (not depicted). Lungs were har-
vested 6 h after treatment with cytokine and evaluated for
mRNA expression. Treatment with either IL-4 or IL-13
induced increased mRNA expression levels for eotaxin,
GOB-5, and FIZZ1 in the lung, and this was not inhibited
by pretreatment with 1018 ISS (Fig. 1, A and B). This lack
of effect of 1018 ISS was not due to inhibition of the ac-
tions of ISS by subsequent IL-4 or IL-13 administration, as
genes known to be highly inducible by ISS, such as IP-10,
MIG, and MCP-3, remained elevated after IL-4 or IL-13
treatment (Fig. 1 C and not depicted). In summary, the di-
rect inhibition of IL-4– and IL-13–mediated functions does
not appear to be the mechanism of action of ISS in this
mouse asthma model.
 
1018 ISS does not prevent airway hyperresponsiveness 
induced by IL-13 administration to the lung
 
In addition to inducing STAT-6–regulated genes, IL-13
administration to the lung has also been reported to di-
rectly induce airway hyperresponsiveness to acetylcholine
via a STAT-6–dependent mechanism (20, 29). To test
whether 1018 ISS pretreatment could inhibit IL-13–induced
airway hyperresponsiveness, mice were given three in-
tratracheal doses of IL-13 on consecutive days (5 
 
 
 
g per
day) as described previously (20). For this experiment, mice
were given three (instead of one) intratracheal doses of IL-
13 because, in our experience, this regimen induces a
stronger, more consistent change in airway responsiveness
than a single dose of IL-13. Before the IL-13 treatments,
mice were given one intratracheal administration of 20 
 
 
 
g
1018 ISS, control ODN, or PBS. 1 d after the last IL-13
treatment, airway responsiveness to acetylcholine was mea-
sured. IL-13 caused a substantial increase in the airway
pressure-time index (APTI; Fig. 2), indicating increased
airway reactivity to acetylcholine, and this was unaffected
by pretreatment with 1018 ISS (Fig. 2). In mice treated
with control ODN and IL-13, the mean APTI was not
significantly different from the PBS control.
Upon completion of the APTI measurements, lungs
were harvested to confirm that 1018 ISS did not inhibit gene
induction by the three-dose regimen of IL-13. As expected,
Figure 1. 1018 ISS does not inhibit gene induction by IL-4 or IL-13. 
(A–C) mRNA expression measured in whole lung is shown. Lungs were 
harvested 6 h after intranasal treatment with 5  g IL-4 (A and C) or 5  g 
IL-13 (B). 1 d before cytokine treatment was given, mice were treated 
intranasally with saline (black bars), 20  g 1018 ISS (gray bars), or control 
ODN (white bars). Mice treated with saline only (and no cytokine) are 
represented by hatched bars. All data are expressed as gene/ubiquitin ratio 
(mean   SEM; five mice per group), and * indicates a p-value of  0.05 
when compared with the saline-only treated group. Increased levels of 
eotaxin, GOB-5, and FIZZ1 are observed after IL-4 and after IL-13 treatment, 
which cannot be inhibited by 1018 ISS treatment. Up-regulation of the 
ISS-inducible genes IP-10, MIG, and MCP-3 is observed after 1018 ISS 
treatment both in IL-4– (A) and IL-13–treated mice (not depicted). 
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increased levels of eotaxin, GOB-5, and FIZZ1 mRNA ex-
pression were observed in IL-13–treated mice, and the levels
of these genes were similar in the IL-13–treated/1018 ISS–
pretreated mice (not depicted). Taken together, the experi-
ments in Figs. 1 and 2 clearly demonstrate that pretreatment
with doses of 1018 ISS capable of inhibiting antigen-induced
Th2 responses (see Figs. 3 and 4 below) does not block any
measurable lung response to IL-4 or IL-13.
 
1018 ISS prevents allergen-induced Th2 and Th2-dependent 
gene induction
 
The experiments described above demonstrate that the inhi-
bition by ISS of antigen-driven Th2-mediated effector func-
tions cannot be explained by direct ISS inhibition of those
effector functions. This suggests that 1018 ISS is able to in-
hibit the activation of antigen-specific Th2 cells, although
direct inhibition of polarized Th2 cells by ISS has not previ-
ously been reported. We assessed the activation of Th2 cells
by antigen in situ by measuring increases in the Th2 cell cy-
tokines IL-4, IL-5, and IL-13 at the protein and mRNA lev-
els in the airways, and by measuring increases in the mRNA
levels of genes directly dependent on IL-4 and IL-13 in the
lung tissue. Mice were sensitized with ragweed pollen ex-
tract (RW) in alum (days 0 and 3) and challenged intratra-
cheally (day 10) with 200 
 
 
 
g RW or PBS. 1 d before chal-
lenge (day 9), the mice were treated with 20 
 
 
 
g 1018 ISS,
control ODN, or PBS. 48 h after RW challenge, lungs were
harvested and mRNA levels of a panel of Th2 and Th2-
dependent genes were evaluated using quantitative PCR.
Challenge with RW induced a marked increase in IL-4, IL-5,
and IL-13 mRNA as well as in the expression of Th2-
dependent genes, such as the chemokines eotaxin, TARC,
MDC, and TCA-3, and the goblet cell genes, GOB-5 and
FIZZ1 (Fig. 3). Pretreatment with 1018 ISS, however, com-
pletely prevented increases in these Th2 and Th2-dependent
genes in the lung (Fig. 3). Expression levels in the RW-chal-
lenged/1018 ISS–pretreated mice were reduced to the levels
observed in control mice that were sensitized but challenged
with PBS only. Treatment with control ODN caused no
significant inhibition of allergen-induced gene expression
(not depicted). These data clearly indicate that 1018 ISS pre-
vents antigen-mediated activation of Th2 cells as measured
directly in the lung.
 
1018 ISS inhibits allergen-induced airway hyperresponsiveness, 
eosinophilia, and Th2 cytokine production
 
To determine whether this inhibition of Th2 gene expres-
sion by 1018 ISS correlated with the inhibition of major fea-
tures of asthma in this model, mice were sensitized, RW
challenged, and treated with 1018 ISS 1 d before RW chal-
lenge as described in the preceding section. 48 h after RW
challenge, airway responsiveness to acetylcholine was mea-
sured and airway inflammation was assessed by the number
of eosinophils in the bronchoalveolar lavage (BAL) compart-
ment. RW challenge in sensitized mice induced a significant
increase in airway responsiveness when compared with con-
trol-challenged animals (Fig. 4, top left). As observed in sim-
ilar experiments using OVA (5), pretreatment with 1018 ISS
was able to significantly inhibit the development of airway
hyperresponsiveness (49% inhibition), whereas pretreatment
with control ODN had no effect. A similar result was ob-
tained with BAL eosinophils. RW challenge induced in-
filtration of eosinophils into the BAL compartment, and
Figure 2. 1018 ISS does not prevent IL-13–induced airway 
hyperresponsiveness. Airway responsiveness to acetylcholine was measured 
in mice exposed to three intratracheal treatments with 5  g IL-13. 1 d 
before the IL-13 treatment started, mice were treated intratracheally with 
PBS (black bar), 20  g 1018 ISS (gray bars), or control ODN (white bar). 
Mice treated with PBS only (and no IL-13) are represented by the hatched 
bar. Airway responsiveness measurements were taken 1 d after the last IL-13 
treatment. Airway responsiveness is defined by the time-integrated change 
in peak airway pressure or the APTI. Data shown are mean   SEM of seven 
mice per group, and * indicates a p-value of  0.05 when compared with 
the PBS-only treated group. A significant increase in airway responsiveness 
is observed after IL-13 treatment. Treatment with 1018 ISS is not able to 
inhibit IL-13–induced airway hyperresponsiveness.
Figure 3. 1018 ISS prevents allergen-induced Th2 and Th2-depen-
dent gene induction. mRNA expression measured in whole lung is shown. 
Mice were sensitized with RW and alum on days 0 and 3. Lungs were 
harvested 48 h after intratracheal challenge (day 10) with 200  g RW in 
sensitized mice. 1 d before the RW challenge, mice were given PBS (black 
bars), 20  g 1018 ISS (gray bars), or control ODN (not depicted) 
intratracheally. Mice challenged with PBS only (and not with RW) are 
represented by white bars. All data are expressed as gene/ubiquitin ratio 
(mean   SEM; five mice per group), and * indicates a p-value of  0.05 
when compared with the PBS-only challenged group. RW challenge in 
sensitized mice induces significant up-regulation of Th2 and Th2-dependent 
genes 48 h after challenge. Treatment with 1018 ISS completely inhibits 
the induction of these genes. 
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pretreatment with 1018 ISS prevented the influx of these
inflammatory cells (92% inhibition; Fig. 4, top right panel).
RW challenge in sensitized mice also induced readily mea-
surable IL-13 and IL-5 protein in the BAL fluid (Fig. 4, bot-
tom left and right panels, respectively). Levels of both cyto-
kines were significantly reduced by treatment with 1018 ISS
(IL-13: 76% inhibition; IL-5: 82% inhibition), but not con-
trol ODN, confirming the inhibition of the mRNAs encod-
ing these cytokines. In summary, it is clear that a single intra-
nasal dose of 1018 ISS is able to inhibit antigen-dependent
activation of Th2 cells in the lung as assessed by a number of
physiological and molecular techniques.
 
APCs from the airways of 1018 ISS–treated mice do not 
activate Th2 cells in vitro
 
Based upon our current understanding of the biological ac-
tivities of ISS, it is likely that the observed inhibition of
Th2 cell activation is due to actions on TLR-9
 
 
 
 APCs
rather than on TLR-9
 
 
 
 T cells. This was examined directly
by testing the APC function of CD11c
 
 
 
 cells derived from
the lungs of mice treated with 1018 ISS and challenged
with antigen. Mice were sensitized with OVA in alum
(days 0 and 7). OVA was used instead of RW in these ex-
periments as we had previously optimized conditions for
stimulation of Th2 cells with APC from OVA-challenged
mice. On day 13, mice were treated with 20 
 
 
 
g 1018 ISS,
control ODN, or saline, and then on day 14 they were
challenged with OVA aerosol. 24 h after OVA challenge,
Figure 4. 1018 ISS inhibits allergen-induced airway hyperresponsive-
ness, eosinophilia, and Th2 cytokine production. Mice were sensitized 
with RW and alum (days 0 and 3) and challenged intratracheally on day 10 
with 200  g RW. 1 d before the challenge, the mice were treated via 
intratracheal administration of PBS (black bars), 20  g 1018 ISS (gray bars), 
or control ODN (white bars). Mice challenged with PBS only (and not with 
RW) are represented by hatched bars. 2 d after challenge, airway 
responsiveness (top left) and the absolute number of eosinophils in the 
BAL (top right) were measured. In the same mice, IL-13 and IL-5 protein 
levels were determined in BAL fluid by ELISA (bottom left and right, 
respectively). Data shown are mean   SEM of 10 mice per group, and 
* indicates a p-value of  0.05 when compared with the PBS-only challenged 
group. RW challenge in sensitized mice significantly increases airway 
responsiveness, the number of eosinophils, and IL-13 and IL-5 levels in 
BAL fluid. Treatment with 1018 ISS significantly inhibits all four of these 
features of allergic asthma.
Figure 5. Antigen-presenting CD11c  cells from the airways of 
1018 ISS–treated mice do not activate Th2 cells in vitro. IL-13, IL-5, 
and IFN-  protein levels as measured by ELISA in culture supernatant are 
shown. A twofold dilution series of irradiated CD11c  cells from the airways 
(starting at 4   106 cells/ml) was incubated with a constant number of 
CD4 /MEL14low T cells (106 cells/ml) in 96 U-bottom wells for 72 h (total vol, 
200  l). The CD11c  cells were derived from the airways of sensitized and 
OVA-challenged mice treated in vivo with saline (black circles), 20  g 1018 
ISS (black squares), or control ODN (white circles). CD4 /MEL14low T cells 
were derived from the spleens of OVA-sensitized mice. Data shown are 
averaged from three separate experiments (mean   SEM), and * indicates a 
p-value of  0.05 when compared with the response measured with CD11c  
cells from OVA-challenged/saline-treated mice. CD11c  cells derived from 
OVA-challenged/saline-treated mice induce high levels of Th2 cytokines in 
the cultures. This is in sharp contrast to the low levels induced by CD11c  
cells from OVA-challenged/1018 ISS–treated mice, demonstrating that these 
CD11c  cells prevent the activation of Th2 cells in vitro. IFN-  levels are not 
changed, regardless of which in vivo pretreatment is applied. 
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lungs were harvested and CD11c
 
 
 
 cells were selected from
the lung and irradiated. Our previous work has shown that
1 d after allergen challenge, the majority of cells presenting
antigen in the airways are CD11c
 
 
 
 (30). A dilution series
of these CD11c
 
 
 
 APCs was incubated with a constant
number of CD4
 
 
 
/MEL14
 
low
 
 T cells isolated from the
spleens of OVA-sensitized mice. When CD11c
 
 
 
 APCs
were derived from allergen-challenged/saline-treated mice,
high levels of IL-13 and IL-5 were induced, indicating effi-
cient Th2 cell activation in these cultures (Fig. 5). In con-
trast, responses of both cytokines were greatly reduced at
all APC doses when APCs were derived from allergen-
challenged 1018 ISS–treated mice (inhibition at 8 
 
 
 
 10
 
5
 
APCs/2 
 
 
 
 10
 
5
 
 T cells: 82 and 83%, respectively, for IL-13
and IL-5 when compared with saline-treated mice; Fig. 5).
Although APCs from control ODN-treated mice were
slightly less active than APCs from saline-treated mice,
they were still very capable of stimulating Th2 cells in a
dose-dependent manner. APCs from 1018 ISS-treated
mice were not completely disabled as they were capable of
stimulating an IFN-
 
 
 
 response from the relatively small
Th1 cell population among the primed splenic T cells (Fig.
5). Our results demonstrate that 1018 ISS treatment in vivo
alters the function of the airway APCs such that they pre-
vent the activation of allergen-specific Th2 cells in vitro.
 
1018 ISS prevents induction of costimulatory molecules 
on airway APCs
 
In an attempt to elucidate why ISS treatment of allergic mice
renders APCs in the airways unable to effectively activate
Th2 cells, ISS-induced changes in the expression of mole-
cules important for APC function were assessed. CD11c
 
 
 
cells derived from the airways of OVA-sensitized mice
treated intranasally 1 d before allergen challenge with either
saline or 1018 ISS were stained with antibodies to CD11c,
B220, and the plasmacytoid dendritic cell (PDC)–specific
antibody anti–PDCA-1, as well as with a variety of antibod-
ies directed against costimulatory molecules, adhesion mole-
cules, and MHC class II. CD11c
 
 
 
/PDCA-1
 
 
 
 cells from the
airways of 1018 ISS–treated mice consistently expressed
lower levels of MHC class II molecules on the cell surface
when compared with CD11c
 
 
 
/PDCA-1
 
 
 
 cells from allergic
mice treated with saline (Fig. 6, top). Interestingly, even
though ISS are known inducers of dendritic cell maturation
in vitro, expression of costimulatory molecules, including
programmed cell death ligand (PD-L)1 and PD-L2, CD40,
and inducible T cell costimulator (ICOS), was substantially
lower on CD11c
 
 
 
/PDCA-1
 
 
 
 cells from 1018 ISS–treated
mice when compared with the same cell population derived
from the airways of allergic mice treated with saline (Fig. 6,
top). Smaller differences were measured in the expression of
Figure 6. 1018 ISS prevents the induction of costimulatory molecules 
on airway APCs. CD11c  cells were derived from the airways of OVA-
sensitized and -challenged mice treated in vivo with saline (shaded area) 
or 20  g 1018 ISS (black line). Cells were stained with antibodies directed 
against CD11c, PDCA-1, B220, and a variety of costimulatory molecules, 
adhesion molecules, and MHC class II, including I-Ad, PD-L1, PD-L2, PD-1, 
CD40, CD80, CD86, and ICOS. Expression levels were analyzed in CD11c /
PDCA-1  cells (airway APCs; top) and CD11c /PDCA-1  cells (airway PDCs; 
bottom). Airway APCs derived from OVA-challenged/1018 ISS–treated mice 
display lower expression levels of MHC class II and various costimulatory 
molecules than observed in OVA-challenged/saline-treated mice, whereas 
airway PDCs derived from 1018 ISS–treated mice display higher levels of 
PD-1 and ICOS compared with their saline-treated counterparts. 
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CD80, CD86, or programmed cell death protein 1 (PD-1);
however, CD11c /PDCA-1  cells from 1018 ISS–treated
mice consistently expressed lower levels than those observed
in saline-treated allergic mice. In allergic mice, the popula-
tion of CD11c /PDCA-1  cells expressing the highest lev-
els of costimulatory molecules also expressed B220, consis-
tent with previous work describing CD11c /B220  cells as
the predominant APCs in the airways (30). It is this popula-
tion that demonstrates the greatest reduction in the expres-
sion of MHC class II and costimulatory molecules in 1018
ISS–treated mice. Thus, the overall pattern of reduced ex-
pression of molecules critical for antigen presentation pro-
vides support for the observation that CD11c  cells derived
from 1018 ISS–treated mice are unable to activate Th2 cells
in vitro and in vivo.
Concurrent with changes in the CD11c /PDCA-1 
population, airway PDCs defined as CD11c /PDCA-1 
cells derived from 1018 ISS–treated mice demonstrated a
ninefold higher percentage of cells expressing the inhibitory
molecule PD-1 compared with PDCs from saline-treated al-
lergic mice (47% in 1018 ISS–treated mice vs. 5.3% in sa-
line-treated mice; Fig. 6, bottom). In addition, PDCs from
the airways of 1018 ISS–treated mice displayed increased
levels of ICOS (25.2% in 1018 ISS–treated mice vs. 4.4% in
saline-treated mice). No other differences in costimulatory
molecule, adhesion molecule, or MHC class II expression
were observed (Fig. 6, bottom). PD-1 acts as an important
negative regulator of T cell responses (31), and it might be
significant that this molecule is induced after in vivo treat-
ment with 1018 ISS on TLR-9  PDCs in the airways. We
speculate that activation of this inhibitory pathway may very
well contribute to the inhibition of the Th2 response observed
after ISS treatment.
1018 ISS inhibits IL-4 secretion and IL-4–mediated gene 
induction upon IgE cross-linking
Using the expression of such cytokines as IL-4 and IL-13 to
measure the activation of Th2 cells in the lungs has a signifi-
cant limitation. Allergic airways are rich in non–T cells capa-
ble of producing type 2 cytokines in response to allergen
challenge. Previous work has shown that Fc RI-bearing
cells, primarily mast cells and basophils, are the major source
of IL-4 in the lung in the first few hours after allergen chal-
lenge, whereas at later times after challenge, IL-4 derives
increasingly from activated Th2 cells (32). To determine
whether ISS treatment was able to inhibit type 2 cytokine
secretion from mast cells, basophils, and Th2 cells, we first
investigated whether pretreatment with 1018 ISS was able to
inhibit allergen-induced gene induction at an early time
point after challenge. Mice were sensitized, treated with ISS,
and challenged with RW as illustrated in Fig. 3, but the
lungs were harvested at 6 h rather than 48 h after allergen
challenge. In initial experiments (not depicted), many Th2-
derived and Th2-dependent genes were highly induced as
early as 6 h after challenge. In this series of experiments, all
of the allergen-induced genes that were elevated at 48 h
(Fig. 3) were observed to be significantly elevated by 6 h af-
Figure 7. 1018 ISS prevents allergen-induced Th2 and Th2-depen-
dent gene induction at an early time point after challenge. mRNA 
expression measured in whole lung is shown. Mice were sensitized with 
RW and alum on days 0 and 3. Lungs were harvested 6 h after intratracheal 
challenge (day 10) with 200  g RW in sensitized mice. 1 d before the RW 
challenge, mice were given PBS (black bars), 20  g 1018 ISS (gray bars), 
or control ODN (not depicted) intratracheally. Mice challenged with PBS 
only (and not with RW) are represented by white bars. All data are expressed 
as gene/ubiquitin ratio (mean   SEM; five mice per group), and * indicates 
a p-value of  0.05 when compared with the PBS-only challenged group. 
RW challenge in sensitized mice induces significant up-regulation of Th2 
and Th2-dependent genes 6 h after challenge. Pretreatment with 1018 ISS 
completely inhibits the induction of these genes, with the exception of IL-4.
Figure 8. 1018 ISS also inhibits the induction of Th2-dependent 
genes after challenge with anti-IgE antibodies in sensitized mice. 
mRNA expression measured in whole lung is shown. Mice were sensitized 
with RW and alum on days 0 and 7. Lungs were harvested 6 h after intranasal 
challenge (day 14) of sensitized mice with 5  g RW (A) or 50  g anti-IgE 
antibodies (EM-95; B). 1 d before the RW or anti-IgE challenge, mice were 
given intranasal saline (black bars), 20  g 1018 ISS (gray bars), or control 
ODN (white bars). Mice challenged with saline only (and not with RW or 
anti-IgE) are represented by hatched bars. All data are expressed as 
gene/ubiquitin ratio (mean   SEM; five mice per group), and * indicates a 
p-value of  0.05 when compared with the saline-only challenged group. 
Intranasal challenge of sensitized mice with RW or anti-IgE antibodies 
up-regulates IL-4, TARC, MDC, and GOB-5 mRNA expression. Pretreatment 
with 1018 ISS completely prevents the induction of TARC, MDC, and 
GOB-5 mRNA expression.JEM VOL. 202, December 5, 2005 1569
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ter allergen challenge in the group pretreated with saline
(Figs. 7 and 8 A). In the 1018 ISS-treated mice, however,
the induction of these genes was completely inhibited (Figs.
7 and 8 A), with the consistent exception of IL-4 mRNA.
But as shown below, IL-4 protein secretion into BAL fluid is
strongly inhibited by 1018 ISS at this time point.
The finding that early cytokine and chemokine induc-
tion is extensively inhibited by 1018 ISS treatment strongly
suggests ISS inhibition of mast cell and basophil as well as T
cell responses; however, gene expression at 6 h after allergen
challenge does not conclusively demonstrate this as measure-
ments at the early time point include both T and non–T cell
sources of cytokine. To assess directly the effect of 1018 ISS
on IgE-triggered pathways, mice primed with RW (days 0
and 7) were challenged (day 14) with anti-IgE instead of an-
tigen. A subset of the genes induced by RW challenge (Fig.
8 A) was strongly induced with anti-IgE challenge: IL-4 and
three of the most highly IL-4–inducible genes, TARC,
MDC, and GOB-5 (Fig. 8 B). The IL-4–induced genes
were very effectively inhibited by 1018 ISS pretreatment
(Fig. 8 B); however, as observed in Figs. 7 and 8 A, IL-4
mRNA was not inhibited. As neither IL-13 protein nor
mRNA levels were significantly elevated by anti-IgE chal-
lenge (not depicted), it was not obvious why the induction
of genes regulated by IL-4 was inhibited, whereas IL-4
mRNA itself was not. One possible explanation was tested
by measuring IL-4 protein recovered from the BAL fluid 6 h
after anti-IgE challenge (Fig. 9). This resolved the paradox
by showing that 1018 ISS was a potent inhibitor of induced
IL-4 at the protein level, despite the lack of effect on IL-4
mRNA induction. Some Fc R1  cells have been shown to
store IL-4 in granules for subsequent release (33), providing
a possible explanation for the uncoupling of transcription
and translation of IL-4 mRNA in this experimental setting.
DISCUSSION
CpG-containing ISS have shown significant promise for pre-
venting allergic responses to pulmonary allergen challenge
in both mouse (1–11) and primate (12) models of allergic
asthma. They can be delivered systemically (1, 2, 4–6) or di-
rectly to the respiratory tract (1, 3, 6) and can inhibit not
only acute responses to allergen, but also more chronic man-
ifestations, such as airway remodeling (9–12). The response
to a pulmonary allergen involves a series of distinct events
mediated by a number of different cell types and cellular in-
teractions, yet the events and cell types directly inhibited by
ISS are poorly understood. In particular, the rapid and ex-
tensive, albeit transient, inhibition of acute Th2 responses
caused by a single inhaled dose of ISS given before allergen
challenge has yet to be explained.
Two distinct possible mechanisms underlying the imme-
diate inhibition of the Th2 response by ISS were evaluated
in this study. The first was inhibition by ISS of the effector
functions mediated by the Th2 cell–dependent cytokines IL-4
and IL-13. Administration of IL-4 and IL-13 to the airways
has been shown to induce many characteristics of allergic
asthma, such as airway hyperresponsiveness, mucus produc-
tion, and gene induction via a STAT-6–dependent mecha-
nism (20–22, 29). Despite the known antagonism of IL-12,
IFN- , and IFN-  on many IL-4– and IL-13–mediated ac-
tivities (23–28), our data demonstrate clearly that this mech-
anism appears to contribute little to the inhibition of allergen
challenge by ISS.
The second possible mechanism evaluated in our study
was ISS-induced inhibition of Th2 cell activation. Th2 re-
sponses were measured directly in the lung by measuring the
expression of Th2 and Th2-dependent genes in whole lung
mRNA and confirming the expression of key cytokines by
immunoassay of BAL fluid. ISS pretreatment resulted in ex-
tensive or complete inhibition of allergen-induced expres-
sion of the definitive Th2 cell genes, IL-4, IL-5, and IL-13,
as well as all of the IL-4/IL-13–inducible genes we have
tested. This direct evidence of Th2 cell inhibition was con-
firmed by a comparable inhibition of Th2-dependent airway
hyperresponsiveness, eosinophilia, and Th2 cytokine pro-
teins in the BAL fluid. These results constitute a comprehen-
sive analysis of the T cell response to allergen challenge in the
lung itself and are consistent with earlier studies that measured
cytokines by ELISA and ELISPOT techniques (2–4).
Fc RI-bearing cells, such as mast cells and basophils,
have been described to be a major source of IL-4 in the air-
ways in the first few hours after allergen challenge, whereas
at later times, IL-4 is increasingly derived from activated Th2
cells (32). The virtually complete inhibition of IL-4–induced
genes and functions suggested that these non–T cell sources
might also be inhibited by ISS. This could be a direct effect
of ISS as it has been shown that mast cells and basophils are
TLR-9  (34, 35) and respond to ISS stimulation with the
production of IL-6 and TNF-  (36). This hypothesis was
tested by challenge of allergic mice with anti-IgE antibodies
rather than with allergen. Anti-IgE challenge induced IL-4
Figure 9. 1018 ISS prevents anti-IgE–induced IL-4 protein production 
in the BAL fluid of sensitized mice. IL-4 protein levels as measured by 
ELISA in BAL fluid are shown. Mice were sensitized with RW and alum on 
days 0 and 7. BAL fluid was harvested 6 h after intranasal challenge (day 
14) with 50  g anti-IgE antibodies (EM-95) in sensitized mice. 1 d before 
challenge, mice were treated intranasally with saline (black bar), 20  g 
1018 ISS (gray bar), or control ODN (white bar). Mice challenged with 
saline only (and not with anti-IgE) are represented by the hatched bar. 
Data shown are mean   SEM of five mice per group, and * indicates a 
p-value of  0.05 when compared with the saline-only challenged group. 
Intranasal challenge of RW-sensitized mice with anti-IgE antibodies 
induces IL-4 protein production in BAL fluid, which is completely inhibited 
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secretion into the BAL fluid within 6 h, and this was indeed
substantially inhibited by pretreatment with 1018 ISS. This
was further confirmed by a profound reduction in the ex-
pression of the IL-4–inducible genes GOB-5, TARC, and
MDC in the mice pretreated with 1018 ISS, indicating that
biologically active IL-4 (and IL-13) had not been secreted.
Although 1018 ISS did not significantly inhibit the early,
mostly non–T cell–derived increase in IL-4 mRNA, it was
clear that this IL-4 mRNA did not result in secreted IL-4
protein in ISS-treated mice. Taken together, these findings
show that a single-dose pretreatment of ISS inhibits allergic
airway responses by blocking the two key initial cellular
events: cytokine release by mast cells and basophils by anti-
gen cross-linking of IgE and cytokine production by aller-
gen-activated Th2 cells. These actions are sufficient to ex-
plain the extensive inhibition—observed by us and many
other groups—on the consequences of those initial cellular
events: airway hyperresponsiveness, eosinophilia, goblet cell
hyperplasia, mucus secretion, and airway remodeling (1–11).
One consequence of allergen-mediated IgE cross-linking
may not, however, be affected by ISS treatment, degranula-
tion, and release of such mediators as histamine and seroto-
nin. Ikeda et al. (34) have reported that ISS does not inhibit
the process of IgE-mediated degranulation, and we have con-
firmed this by measuring the immediate drop in body tem-
perature after anti-IgE challenge. Challenge with anti-IgE as
illustrated in Fig. 8 caused a transient reduction in rectal tem-
perature from 38.1   0.1 C before challenge to a minimum
of 35.8   0.1 C at 45 min postchallenge, consistent with an
immediate response to IgE-mediated mast cell and basophil
degranulation. A similar temperature drop was observed after
anti-IgE challenge of sensitized/1018 ISS-treated mice, sug-
gesting no inhibition of degranulation by ISS (Fig. S1, avail-
able at http://www.jem.org/cgi/content/full/jem.20050631/
DC1). Chen et al. (37) have reported that IFN-  inhibits IL-3–
primed IL-4 and IL-13 secretion from human basophils,
whereas histamine and leukotriene C4 release was unaf-
fected, providing additional evidence that cytokine and
mediator release are regulated quite differently.
The nearly complete absence of allergen-induced Th2
cytokines combined with the absence of transcriptional and
functional responses to those cytokines after ISS treatment
demonstrated clearly that Th2 cell activation in the lung was
inhibited by recent exposure to ISS. This was not a result of a
change in the Th1/Th2 cell ratio as there was no evidence of
a corresponding increase in the allergen-specific Th1 re-
sponse. One possible mechanism for the failure of Th2 acti-
vation in ISS-treated mice could be inhibition of the migra-
tion of Th2 cells into the lung. This could account for part of
the reduced Th2 response, particularly at the 48-h postchal-
lenge time point. We have observed partial inhibition of
CD4  T cell infiltration at 48 h in ISS-pretreated mice (not
depicted), but this would not explain the virtually complete
inhibition of Th2 responses we have observed as substantial
numbers of antigen-specific Th2 cells reside in the lungs of
primed mice, even before the first pulmonary challenge (30).
The principal mechanism for Th2 inhibition in this model
appears to be inhibition of the ability of lung APCs to acti-
vate differentiated Th2 cells. Antigen-presenting CD11c 
cells derived from the lungs of sensitized and challenged mice
treated in vivo with 1018 ISS failed to induce Th2 cell cyto-
kine production in CD4 /MEL14  T cell populations from
primed spleen cells in vitro. This activity is not revealed in a
complete in vitro system. The addition of 1018 ISS to the
cultures of CD4 /MEL14  T cells and antigen-presenting
CD11c  cells derived from the airways of allergen-chal-
lenged mice did not inhibit Th2 cell cytokine production
(not depicted). Thus, 1018 ISS needs to act in vivo in the
presence of components of the lung microenvironment in
order to have an inhibitory effect. This may explain why the
ability of ISS to inhibit recall responses of fully polarized Th2
cells has not been reported previously.
We evaluated several potential mechanisms by which ISS
may alter the function of CD11c  APCs. One of these was
involvement of the rate-limiting enzyme of the tryptophan
catabolism, indoleamine 2,3-dioxygenase (IDO). Increased
levels of IDO lead to the enhanced degradation of the essen-
tial amino acid tryptophan, which in turn has been shown to
inhibit T cell responses (38). ISS are capable of inducing
increased levels of IDO in both lung epithelial cells and
CD11c  dendritic cells (38, 39), making IDO a candidate by
which CD11c  APCs could mediate the abrogation of Th2
cell activation that occurs after treatment with ISS. In a
somewhat different model of murine asthma, inhibitors of
IDO have been shown to reverse the protective effects of
systemic ISS (39). In our models, we were able to measure a
significant increase in pulmonary IDO mRNA levels after
ISS treatment (Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20050631/DC1); however, this did
not result in significant IDO enzymatic activity (not de-
picted). Furthermore, subcutaneous implantation of slow-
release pellets containing the IDO inhibitor 1-methyl-DL-
tryptophan (M-trp) did not affect ISS-induced inhibition of
the Th2 response (Fig. S3). Thus, in our models, IDO does
not play a decisive role in the ISS-mediated inhibition of the
Th2 response in the airways, and APCs of 1018 ISS–treated
mice most probably use mechanisms other than IDO to
down-regulate Th2 cell activation.
A second potential mechanism evaluated was an ISS-
induced change in costimulatory molecule expression on the
APCs. Costimulation is a critical component of APC function
and various costimulatory molecules have important roles in
stimulating effector T cell responses (for review see reference
31). We observed a drastic reduction in the overall expression
of costimulatory molecules on CD11c  APCs from the air-
ways of ISS-treated mice, including PD-L1, PD-L2, CD40,
ICOS, CD80, CD86, and PD-1, accompanied by a clear re-
duction in the expression of MHC class II molecules, creating
an overall picture of a much less competent APC. ISS may
very likely induce these changes via a direct action on the
APCs themselves as most APC subsets in the mouse express
TLR-9 and respond to ISS (15). Alternatively, this might beJEM VOL. 202, December 5, 2005 1571
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regulated via indirect effects via other cell types. Of interest is
our observation that in vivo ISS treatment induced the ex-
pression of the inhibitory molecule PD-1 on TLR-9  PDCs
in the airways. Serebrisky et al. (4) investigated changes in co-
stimulatory molecule mRNA expression levels in the airways
after in vivo treatment with ISS. They observed that ISS-
induced inhibition of the Th2 cell response was accompanied
with an up-regulation in CD80 mRNA expression levels and
decreased levels of CD86 mRNA. In contrast to our study,
however, these changes were measured in whole lung.
In summary, we demonstrate that ISS do not act on cy-
tokine-mediated effector pathways, but rather prevent Th2
cytokine secretion from both Th2 cells as well as IgE-activated
cells, such as mast cells and basophils. In vivo treatment with
ISS decreases the expression of MHC class II and costimula-
tory molecules on CD11c  APCs in the airways, resulting in
APCs that fail to activate Th2 cells. Inhibition of both the Th2
and the IgE-mediated pathway enhances the prospects for suc-
cessful therapeutic application of ISS in allergic asthma and re-
veals an exiting new mechanism of action of ISS.
MATERIALS AND METHODS
In vivo treatment with IL-4, IL-13, or ISS. Animal experiments de-
scribed in our studies were performed at Northview Pacific Laboratories
Inc. or at the animal facility of the Division of Immunobiology, Cincinnati
Children’s Hospital Medical Center, and all procedures applied were Insti-
tutional and Animal Care Use Committee–approved.
6–8-wk-old female BALB/c mice were anesthetized with isoflurane
and treated intranasally with 5  g IL-4 or IL-13 (R&D Systems) in 50  l
of pyrogenic-free saline. 1 d before IL-4 or IL-13 treatment, the mice
were pretreated intranasally with 20  g ISS or control ODN in 50  l sa-
line. The ISS and two control ODNs used in our experiments were 1018
ISS (5 -TGACTGTGAACGTTCGAGATGA), 1040 (5 -TGACTGT-
GAACCTTAGAGATGA), and C661 (5 -TGCTTGCAAGCTTG-
CAAGCA), respectively. All sequences used had  5 endotoxin units per
mg of ODN as determined by Limulus amebocyte lysate assay (BioWhit-
taker). Sequences were synthesized as described previously (40). To in-
duce IL-13–mediated airway hyperresponsiveness, mice were treated
three times with 5  g IL-13 on consecutive days (days 1–3) as described
previously (20). Before the IL-13 treatments, one 20- g ISS treatment
(day 0) was administered. In this particular set of experiments, IL-13 and
ISS were given intratracheally.
Ragweed sensitization and allergen or anti-IgE challenge. 6–8-wk-
old female BALB/c mice were intraperitoneally sensitized with 150  g de-
fatted RW (Ambrosia artemissifolia; Greer Laboratories) and alum on days 0
and 3. On day 9, the mice were pretreated with 20  g ISS, control ODN,
or diluent control via intratracheal administration under ketamine/xylazine
anesthesia. On day 10, the mice were intratracheally challenged with 200
 g RW or diluent control (41).
In a second series of experiments, a different sensitization was used.
Mice were intraperitoneally sensitized with 10  g RW in alum on days 0
and 7. On day 13, the mice were pretreated with 20  g ISS, control ODN,
or saline via intranasal administration. On day 14, these mice were chal-
lenged intranasally with 5  g RW, 50  g anti–mouse anti-IgE antibodies
(EM95), or with saline. The anti–mouse anti-IgE antibodies were provided
by F. Finkelman (University of Cincinnati, Cincinnati, OH).
Airway responsiveness measurements and assessment of airway in-
flammation. Airway responsiveness to intravenous acetylcholine was
measured as described previously (42). In brief, 1 d after the last IL-13 treat-
ment or 2 d after RW challenge, mice were anesthetized with sodium pen-
tobarbital, intubated, and ventilated at a rate of 120 breaths/min with a con-
stant tidal volume of 0.2 ml. After recording a stable baseline airway
pressure, mice were paralyzed with decamethonium and injected intrave-
nously with 50  g/kg acetylcholine.
After airway responsiveness measurements, lungs were lavaged thor-
oughly with saline. BAL cells were separated from BAL fluid by centrifugation
and counted. Cytospins were prepared and stained with Wright-Giemsa.
Differential cell counts were obtained using oil immersion microscopy. At
least 500 cells were counted per cytospin.
Isolation of T cells and airway APCs as well as flow cytometric
analysis. Mice were intraperitoneally sensitized with 10  g OVA (grade 5;
Sigma-Aldrich) in alum on days 0 and 7. For T cell isolation, spleens were
harvested 1 wk after sensitization (day 14). For isolation of airway allergen-
presenting cells, sensitized mice were pretreated on day 13 with 20  g ISS,
control ODN, or saline via intranasal administration. 1 d later (day 14), the
mice were challenged with 5 mg/ml of an OVA aerosol for 45 min. 24 h
after challenge lungs were removed. Both the spleen and lungs were minced
and incubated with 0.02 mg/ml DNase I (Sigma-Aldrich) and 1 mg/ml col-
lagenase D (Roche) for 30 min at 37 C while shaking. Single cell suspen-
sions were prepared, the red blood cells were lysed, and cell suspensions
were thoroughly washed. For the spleen, the cells were first depleted for
B220 , CD8 , and CD11b  cells using MACS microbeads and MACS LD
columns (both from Miltenyi Biotec) according to the manufacturer’s in-
structions. The remaining cells were then stained with fluorescently labeled
anti-MEL14 (MEL-14; BD Biosciences) and anti-CD4 antibodies (GK1.5;
BD Biosciences), and subsequently sorted for CD4 /MEL14low cells using a
MoFlo high speed sorter (DakoCytomation). After sorting, the CD4 /
MEL14low cells were washed and counted. For the lung, adherent cells were
removed by incubating the cell suspension in a Petri dish for 1 h at 37 C.
CD11c  cells were then selected from the nonadherent cell population us-
ing the appropriate MACS microbeads and MACS LD columns according
to the manufacturer’s instructions. The CD11c  cells were irradiated,
washed, and counted.
Flow cytometric analysis of CD11c  cells isolated from the airways was
performed using a BD FACSCalibur (BD Biosciences) after staining with
monoclonal antibodies directed against a variety of costimulatory molecules,
adhesion molecules, and MHC class II. Antibodies included anti-CD11c
(HL-3), anti-B220 (RA3-6B2), anti–I-Ad (AMS-32.1), anti–PD-L1
(MIH5), anti–PD-1 (J43), anti-CD40 (3/23), anti-CD80 (16-10A1), anti-
CD86 (GL1), anti-ICOS (7E.17G9; all from BD Biosciences), anti–PDCA-1
(Miltenyi Biotec), and anti–PD-L2 (TY25; eBioscience).
In vitro incubation of airway APCs and T cells. A twofold dilution
series of CD11c  cells isolated from the airways (starting at 4   106 cells/
ml) was incubated with a constant number of CD4 /MEL14low T cells (106
cells/ml) in 96 U-bottom wells for 72 h (total vol, 200  l). As a positive
control, wells containing CD11c  cells, CD4 /MEL14low T cells, and
OVA (250  g/ml) were included. The CD11c  cells were derived from
the airways of OVA-sensitized and -challenged mice pretreated in vivo with
saline, 20  g 1018 ISS, or control ODN. CD4 /MEL14low T cells were
derived from the spleens of OVA-sensitized mice. After 72 h of incubation,
supernatant was harvested and tested for the presence of IL-13, IL-5, and
IFN-  cytokines by ELISA.
Cytokine measurement in BAL fluid or culture supernatant. BAL
fluids from individual mice were lyophilized and resuspended in 200  l sa-
line. Levels of IL-4, IL-5, IL-13, and IFN-  protein were measured in BAL
fluid samples or culture supernatants using ELISA kits (R&D Systems) ac-
cording to the manufacturer’s instructions. The lower detection levels were
8, 16, and 8 pg/ml for the IL-4, IL-5, and IL-13 ELISA, respectively. IFN- 
protein levels were assayed by matched antibody pairs (BD Biosciences)
used according to the manufacturer’s instructions. The lower detection
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Quantitation of gene expression by real-time PCR. The protocol
for the analysis of gene expression has been detailed elsewhere (43). In brief,
snap-frozen mouse lungs were homogenized in RLT buffer (QIAGEN) us-
ing a polytron homogenizer. Total RNA was extracted via the RNeasy
Mini Column Protocol (QIAGEN). Of each RNA sample, 5  g was incu-
bated with DNase I (Boerhinger) in the presence of RNAsin (Promega) and
subsequently converted into cDNA using oligo dT (Promega), random
hexamers, and SuperScript RT II (Invitrogen). cDNA was diluted 1:100,
and PCR was conducted using QuantiTect SYBR green PCR master mix
(QIAGEN) combined with primer pairs (Operon) or QuantiTect probe
PCR master mix and PDAR primer pairs with labeled probe (Applied Bio-
systems). PCR reactions were performed using a sequence detector (Gene-
Amp 5700; Applied Biosystems). PCR amplification of the housekeeping
gene ubiquitin was performed for each sample, allowing for normalization
of data. All data are expressed as a gene/ubiquitin ratio.
Data analysis. Data were analyzed with a one-way analysis of variance
followed by a Bonferroni multiple comparisons test. When data groups
demonstrated unequal standard deviations or were not normally distributed,
a Kruskal-Wallis nonparametric analysis of variance was performed followed
by a Dunn’s multiple comparisons test. ELISA data from the culture super-
natants were analyzed with a two-way analysis of variance followed by a
Bonferroni posttest. Analyses were performed with GraphPad InStat, and
P   0.05 was considered significant for all statistical analyses.
Online supplemental material. Fig. S1 shows the change in body tem-
perature measured before and at various time points after intranasal chal-
lenge with anti-IgE antibodies in RW-sensitized mice. 1 d before the chal-
lenge, mice were treated intranasally with either saline or 1018 ISS. These
data demonstrate that challenge of RW-sensitized mice with anti-IgE anti-
bodies significantly decreases the body temperature either in the absence or
presence of 1018 ISS pretreatment. Fig. S2 shows IDO mRNA levels mea-
sured in whole lung after intranasal treatment with saline, 1018 ISS, or con-
trol ODN in naive or Th2-primed mice. Significant IDO expression is ob-
served after the treatment of naive and allergic mice with 1018 ISS. Fig. S3
shows IL-5 and IL-13 protein levels in BAL fluid measured both in the RW
and in the OVA asthma model. Mice were sensitized as described above,
and on day 12, slow-release pellets containing the IDO inhibitor M-trp
were inserted under the dorsal skin. Mice were treated with 1018 ISS and
challenged with allergen as described above, and BAL fluid was harvested
24 h after challenge. These data demonstrate that treatment with 1018 ISS
significantly inhibits the Th2 response in the airways, which is not prevented
by concurrent treatment with M-trp.
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